MENU
+Compare
ERAS
Stock ticker: NASDAQ
AS OF
Apr 24, 04:59 PM (EDT)
Price
$1.39
Change
-$0.03 (-2.11%)
Capitalization
390.91M

ERAS Erasca Forecast, Technical & Fundamental Analysis

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more

ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ERAS with price predictions
Apr 23, 2025

ERAS's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for ERAS moved out of oversold territory on April 09, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on ERAS as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on April 16, 2025. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

ERAS moved above its 50-day moving average on April 23, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in of 190 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ERAS broke above its upper Bollinger Band on April 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.923) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ERAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ERAS is expected to report earnings to rise 15.55% to -12 cents per share on May 08

Erasca ERAS Stock Earnings Reports
Q1'25
Est.
$-0.13
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.11
Q1'24
Missed
by $0.03
The last earnings report on March 20 showed earnings per share of -10 cents, beating the estimate of -12 cents. With 267.40K shares outstanding, the current market capitalization sits at 390.91M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GABSX38.53N/A
N/A
Gabelli Small Cap Growth AAA
JATIX54.29N/A
N/A
Janus Henderson Glb Tech and Innovt I
EAPDX14.91N/A
N/A
Parametric Dividend Income A
KTRZX8.39N/A
N/A
DWS Global Income Builder R6
BLYCX24.63N/A
N/A
American Beacon Man Lg Cp Growth C

ERAS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+2.90%
RVMD - ERAS
53%
Loosely correlated
+1.57%
XNCR - ERAS
53%
Loosely correlated
+2.07%
KYMR - ERAS
52%
Loosely correlated
+6.56%
BEAM - ERAS
50%
Loosely correlated
+3.87%
ELVN - ERAS
50%
Loosely correlated
-1.45%
More